Clinical Research Directory

Inclusion Criteria: * The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is started * Prostate cancer: First course of docetaxel treatment or second-generation antiandrogen treatment for metastatic prostate cancer. * Breast cancer: First-line medical treatment of metastatic breast cancer regardless of hormone receptor status. * Kidney cancer: Kidney cancer, for which 1st-line cancer drug treatment is started as tki monotherapy and/or IO monotherapy or as a combination therapy. * Ovarian cancer: stage III or IV cancer for which chemotherapy treatment is started. * The patient agrees to the study and signs a written informed consent. * Adult (18 years=\>) women (breast, ovarian and kidney cancer) and men (prostate and kidney cancer) are recruited for the study. * In women, the use of a reliable contraceptive during the intervention Exclusion Criteria: * High risk of bone fractures * Inability to physical exertion and/or unsuitability for cancer drug treatment * Poor co-operation ability for psychological reasons * Active use of cholesterol-lowering drugs * Severe liver or kidney failure * Troublesome side effects that occurred in the past during cholesterol medication * Continuous use of medicinal substances that interact with atorvastatin during the study period * A special group of subjects according to the EU Clinical Trials Regulation 536/2014 (e.g. pregnant or lactating women) Exclusion criteria in patients who are already using statin medication before the study: * High risk of bone fractures * Inability to physical exertion and/or unsuitability for cancer drug treatment * Poor co-operation ability for psychological reasons * Severe liver or kidney failure * A special group of subjects according to the EU Clinical Trials Regulation 536/2014 (e.g. pregnant or lactating women)